2026 Q3 -tulosraportti
14 päivää sittenTarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
7,83VWAP
Alin
7,2VaihtoMäärä
3,6 473 646
VWAP
Ylin
7,83Alin
7,2VaihtoMäärä
3,6 473 646
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 1.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 13.2. | ||
2026 Q2 -tulosraportti 13.11.2025 | ||
Vuosittainen yhtiökokous 2025 18.8.2025 | ||
2026 Q1 -tulosraportti 13.8.2025 | ||
2025 Q4 -tulosraportti 1.7.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·18.2.Possibly some of the most important knowledge within ATAI, and the sector, that has been written in a long time! (And yes, I also own ATAI shares) For those of you who own Cybin /Helus shares, I am curious if you see their patents as "more important" than what is mentioned below, especially regarding the time perspective Christian Angelmayer mentions? : Psychedelic Medicines - a Time for Stockpickers https://www.linkedin.com/pulse/psychedelic-medicines-time-stockpickers-christian-angermayer-id47f?utm_source=share&utm_medium=member_android&utm_campaign=share_via *Do your own research*
·18.2.What Christian Angelmayer says about patents almost goes without saying. The fact that one has patents naturally does not prevent other companies from conducting clinical studies on similar molecules. But the fact that a company has strong patents can potentially contribute to commercial success for a long time. If larger companies want to acquire smaller companies like Helus, this is something they value. Through acquisitions or collaborations, they usually have exclusive rights to the drug for a long time, and thus earn good money for a long time. The most important thing is the results of the clinical studies. But I would say that strong IP strengthens the case.
·17.2.Is it because of compass pathways results that Cybin is going up today?
·18.2.Definitely because of compass… all my psy biotech is going up except for bioxcel :)
·10.2.Why is it going up.?
·17.2.(retrieved from the internet): Cybin stock (CYBN) is experiencing today, February 17, 2026, a significant increase of over 8%, which is primarily due to very positive news from their clinical studies. Here are the main reasons for today's jump: 1. Breakthrough in depression study (SPL026) The biggest driver is the publication of results from a Phase 2a study of the substance SPL026 (a short-acting serotonergic agonist) for the treatment of major depressive disorder (MDD). The results: The study met its primary endpoint and showed a clinically significant reduction in depression symptoms after just two weeks compared to placebo. Durability: The effect was observed already after one week and persisted for up to three months for many participants. Publication: The results were published today in the recognized scientific journal Nature Medicine, which provides great credibility in the market. 2. Spillover effect on HLP004 Although Cybin's parent company (Helus Pharma) is not continuing SPL026 in its current form, the data is being used directly to optimize their HLP004 program, which focuses on generalized anxiety disorder (GAD). Investors are reacting positively to the fact that the technology behind their drugs has now been proven effective in a controlled study. 3. Expectation for upcoming data (Q1 2026) The market is currently very attentive to Cybin, as the company is expected to present topline data from their Phase 2 study with HLP004 before the end of the first quarter of 2026. Today's good news increases confidence that the upcoming results will also be positive. 4. Analysts' assessment Several analysts maintain a "Strong Buy" recommendation on the stock with very high price targets (some up to $50-$55), which reinforces buying pressure when concrete positive news like today's emerges.
5.2.5.2.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q3 -tulosraportti
14 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·18.2.Possibly some of the most important knowledge within ATAI, and the sector, that has been written in a long time! (And yes, I also own ATAI shares) For those of you who own Cybin /Helus shares, I am curious if you see their patents as "more important" than what is mentioned below, especially regarding the time perspective Christian Angelmayer mentions? : Psychedelic Medicines - a Time for Stockpickers https://www.linkedin.com/pulse/psychedelic-medicines-time-stockpickers-christian-angermayer-id47f?utm_source=share&utm_medium=member_android&utm_campaign=share_via *Do your own research*·18.2.What Christian Angelmayer says about patents almost goes without saying. The fact that one has patents naturally does not prevent other companies from conducting clinical studies on similar molecules. But the fact that a company has strong patents can potentially contribute to commercial success for a long time. If larger companies want to acquire smaller companies like Helus, this is something they value. Through acquisitions or collaborations, they usually have exclusive rights to the drug for a long time, and thus earn good money for a long time. The most important thing is the results of the clinical studies. But I would say that strong IP strengthens the case.
- ·17.2.Is it because of compass pathways results that Cybin is going up today?·18.2.Definitely because of compass… all my psy biotech is going up except for bioxcel :)
- ·10.2.Why is it going up.?·17.2.(retrieved from the internet): Cybin stock (CYBN) is experiencing today, February 17, 2026, a significant increase of over 8%, which is primarily due to very positive news from their clinical studies. Here are the main reasons for today's jump: 1. Breakthrough in depression study (SPL026) The biggest driver is the publication of results from a Phase 2a study of the substance SPL026 (a short-acting serotonergic agonist) for the treatment of major depressive disorder (MDD). The results: The study met its primary endpoint and showed a clinically significant reduction in depression symptoms after just two weeks compared to placebo. Durability: The effect was observed already after one week and persisted for up to three months for many participants. Publication: The results were published today in the recognized scientific journal Nature Medicine, which provides great credibility in the market. 2. Spillover effect on HLP004 Although Cybin's parent company (Helus Pharma) is not continuing SPL026 in its current form, the data is being used directly to optimize their HLP004 program, which focuses on generalized anxiety disorder (GAD). Investors are reacting positively to the fact that the technology behind their drugs has now been proven effective in a controlled study. 3. Expectation for upcoming data (Q1 2026) The market is currently very attentive to Cybin, as the company is expected to present topline data from their Phase 2 study with HLP004 before the end of the first quarter of 2026. Today's good news increases confidence that the upcoming results will also be positive. 4. Analysts' assessment Several analysts maintain a "Strong Buy" recommendation on the stock with very high price targets (some up to $50-$55), which reinforces buying pressure when concrete positive news like today's emerges.
- 5.2.5.2.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
7,83VWAP
Alin
7,2VaihtoMäärä
3,6 473 646
VWAP
Ylin
7,83Alin
7,2VaihtoMäärä
3,6 473 646
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 1.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 13.2. | ||
2026 Q2 -tulosraportti 13.11.2025 | ||
Vuosittainen yhtiökokous 2025 18.8.2025 | ||
2026 Q1 -tulosraportti 13.8.2025 | ||
2025 Q4 -tulosraportti 1.7.2025 |
2026 Q3 -tulosraportti
14 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 1.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 13.2. | ||
2026 Q2 -tulosraportti 13.11.2025 | ||
Vuosittainen yhtiökokous 2025 18.8.2025 | ||
2026 Q1 -tulosraportti 13.8.2025 | ||
2025 Q4 -tulosraportti 1.7.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·18.2.Possibly some of the most important knowledge within ATAI, and the sector, that has been written in a long time! (And yes, I also own ATAI shares) For those of you who own Cybin /Helus shares, I am curious if you see their patents as "more important" than what is mentioned below, especially regarding the time perspective Christian Angelmayer mentions? : Psychedelic Medicines - a Time for Stockpickers https://www.linkedin.com/pulse/psychedelic-medicines-time-stockpickers-christian-angermayer-id47f?utm_source=share&utm_medium=member_android&utm_campaign=share_via *Do your own research*·18.2.What Christian Angelmayer says about patents almost goes without saying. The fact that one has patents naturally does not prevent other companies from conducting clinical studies on similar molecules. But the fact that a company has strong patents can potentially contribute to commercial success for a long time. If larger companies want to acquire smaller companies like Helus, this is something they value. Through acquisitions or collaborations, they usually have exclusive rights to the drug for a long time, and thus earn good money for a long time. The most important thing is the results of the clinical studies. But I would say that strong IP strengthens the case.
- ·17.2.Is it because of compass pathways results that Cybin is going up today?·18.2.Definitely because of compass… all my psy biotech is going up except for bioxcel :)
- ·10.2.Why is it going up.?·17.2.(retrieved from the internet): Cybin stock (CYBN) is experiencing today, February 17, 2026, a significant increase of over 8%, which is primarily due to very positive news from their clinical studies. Here are the main reasons for today's jump: 1. Breakthrough in depression study (SPL026) The biggest driver is the publication of results from a Phase 2a study of the substance SPL026 (a short-acting serotonergic agonist) for the treatment of major depressive disorder (MDD). The results: The study met its primary endpoint and showed a clinically significant reduction in depression symptoms after just two weeks compared to placebo. Durability: The effect was observed already after one week and persisted for up to three months for many participants. Publication: The results were published today in the recognized scientific journal Nature Medicine, which provides great credibility in the market. 2. Spillover effect on HLP004 Although Cybin's parent company (Helus Pharma) is not continuing SPL026 in its current form, the data is being used directly to optimize their HLP004 program, which focuses on generalized anxiety disorder (GAD). Investors are reacting positively to the fact that the technology behind their drugs has now been proven effective in a controlled study. 3. Expectation for upcoming data (Q1 2026) The market is currently very attentive to Cybin, as the company is expected to present topline data from their Phase 2 study with HLP004 before the end of the first quarter of 2026. Today's good news increases confidence that the upcoming results will also be positive. 4. Analysts' assessment Several analysts maintain a "Strong Buy" recommendation on the stock with very high price targets (some up to $50-$55), which reinforces buying pressure when concrete positive news like today's emerges.
- 5.2.5.2.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
7,83VWAP
Alin
7,2VaihtoMäärä
3,6 473 646
VWAP
Ylin
7,83Alin
7,2VaihtoMäärä
3,6 473 646
Välittäjätilasto
Dataa ei löytynyt